{
    "clinical_study": {
        "@rank": "85823", 
        "arm_group": {
            "arm_group_label": "Folotyn and Leucovorin", 
            "arm_group_type": "Experimental", 
            "description": "Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment). Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.\nFolic acid and Vitamin B12 is given prior to initiation of Folotyn."
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related\n      Grade 3 or higher oral mucositis."
        }, 
        "brief_title": "Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsed Peripheral T-Cell Lymphoma", 
            "Refractory Peripheral T-Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with relapsed or refractory PTCL.\n\n          -  At least 18 years of age.\n\n          -  Recovered from the toxic effects of prior therapy, and is at least 4 weeks from the\n             most recent cytotoxic therapy.\n\n          -  Adequate hematologic, hepatic, and renal function as defined by:\n\n               -  Absolute neutrophil count (ANC) \u22651000/\u03bcL.\n\n               -  Platelet count \u2265100,000/\u03bcL.\n\n               -  Total bilirubin \u22641.5 mg/dL.\n\n               -  AST/SGOT, ALT/SGPT, GGT \u22642.5 \u00d7 ULN,  AST/ALT/GGT \u22645 \u00d7 ULN if documented hepatic\n                  involvement with lymphoma).\n\n               -  Creatinine \u22641.5 mg/dL or calculated creatinine clearance \u226550 mL/min.\n\n          -  ECOG \u22642\n\n        Exclusion Criteria:\n\n          -  Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of\n             the cervix). If there is a history of prior malignancies other than those exceptions\n             listed above, the patient is to be disease-free for \u22655 years. Patients with other\n             prior malignancies less than 5 years before study entry may still be enrolled if they\n             have received treatment resulting in complete resolution of the cancer and currently\n             have no clinical, radiologic, or laboratory evidence of active or recurrent disease.\n\n          -  Congestive heart failure Class III/IV according to the New York Heart Association\n             (NYHA) Functional Classification.\n\n          -  Uncontrolled hypertension.\n\n          -  Known HIV-positive diagnosis.\n\n          -  Symptomatic CNS metastases or lesions for which treatment is required. Prophylactic\n             CNS treatment are eligible.\n\n          -  Active uncontrolled infection, underlying medical condition, or other serious illness\n             that would impair the ability of the patient to receive protocol treatment.\n\n          -  Had major surgery within 14 days prior to enrollment.\n\n          -  Used any investigational drugs, biologics, or devices within 4 weeks prior to study\n             treatment or plans to use any of these during the course of the study.\n\n          -  Had previous exposure to Folotyn within 6 months of study enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106650", 
            "org_study_id": "SPI-FOL-14-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Folotyn and Leucovorin", 
                "intervention_name": "Folotyn and Leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "Pralatrexate (Folotyn)"
            }, 
            {
                "arm_group_label": "Folotyn and Leucovorin", 
                "description": "Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration", 
                "intervention_name": "Folic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Folotyn and Leucovorin", 
                "description": "Vitamin B12 (1 mg IM) is to have been administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.", 
                "intervention_name": "Vitamin B12", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex", 
                "Vitamin B 12", 
                "Hydroxocobalamin", 
                "Leucovorin", 
                "Vitamins", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Relapsed PTCL", 
            "Refractory PTCL"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn\u00ae (Pralatrexate) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)", 
        "overall_contact": {
            "email": "Angie.schinkel@sppirx.com", 
            "last_name": "Angie Schinkel", 
            "phone": "949-743-9257"
        }, 
        "overall_official": {
            "affiliation": "Spectrum Pharmaceuticals, Inc", 
            "last_name": "Pankaj Sharma, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 3 or higher oral mucositis.", 
            "measure": "Grade 3 Oral Mucositis Prevention", 
            "safety_issue": "Yes", 
            "time_frame": "15 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 2 or higher oral mucositis.", 
                "measure": "Grade 2 Oral Mucositis Prevention", 
                "safety_issue": "Yes", 
                "time_frame": "15 weeks"
            }, 
            {
                "description": "To evaluate the effect of leucovorin on the number and proportion of patients whose subsequent dose of Folotyn is omitted, delayed, or reduced due to the onset of oral mucositis.", 
                "measure": "Effectiveness of Leucovorin in Folotyn dose modification", 
                "safety_issue": "Yes", 
                "time_frame": "15 weeks"
            }, 
            {
                "description": "To evaluate overall response rate (ORR) of Folotyn in patients with relapsed or refractory (R/R) PTCL.", 
                "measure": "Overall Response Rate", 
                "safety_issue": "Yes", 
                "time_frame": "17 weeks"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}